Last reviewed · How we verify
NCT05077332
LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)
Phase 2 trial testing Famotidine in 2019 Novel Coronavirus Disease in 4 participants. Completed in 10 November 2025.
10 November 2025
Quick facts
| Lead sponsor | Leidos Life Sciences |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 4 |
| Start date | 29 December 2021 |
| Primary completion | 10 November 2025 |
| Estimated completion | 10 November 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Famotidine (famotidine) — full drug profile →
- Celecoxib (celecoxib) — full drug profile →
- Placebo
Conditions studied
- 2019 Novel Coronavirus Disease — all drugs for 2019 Novel Coronavirus Disease →
- 2019 Novel Coronavirus Infection — all drugs for 2019 Novel Coronavirus Infection →
- 2019-nCoV Disease — all drugs for 2019-nCoV Disease →
- 2019-nCoV Infection — all drugs for 2019-nCoV Infection →
Sponsor
Leidos Life Sciences
Who can join
18 and older, any sex, with 2019 Novel Coronavirus Disease or 2019 Novel Coronavirus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This master protocol serves as a common reference for the inpatient and outpatient clinical studies that share common elements.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The role of traditional NSAIDs and selective COX-2 inhibitors on COVID-19 outcomes: a real-world data study.
Mallah N, Visos-Varela I, Takkouche B, Bugarín-González R, et al · · 2024 · cited 2× · PMID 39312097 · DOI 10.1007/s10787-024-01568-y
Verify or expand the search:
- PubMed search for NCT05077332
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Famotidine
Trials testing the same drug.
- NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
- NCT07101445 — Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injecti · Phase 4 · recruiting
- NCT06743243 — Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia · Phase 4 · enrolling by invitation
- NCT07018635 — A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Adm · Phase 1 · completed
- NCT06819670 — A Study to Prevent Infantile Spasms Relapse · Phase 2 · recruiting
Other Leidos Life Sciences trials
Trials by the same sponsor.
- NCT07190105 — Vagal Approaches on Long COVID-19 · NA · completed
- NCT05085574 — Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1) · Phase 2 · withdrawn
- NCT05077969 — Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patie · Phase 2 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05077332 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Leidos Life Sciences
- Last refreshed: 16 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05077332.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing